J. Sramek

Publications215
h-index32
Citations3,714
Highly Influential Citations91
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • N. Cutler
  • 294 Publications • 9,941 Citations
  • L. Thal
  • 458 Publications • 54,142 Citations
  • M. Farlow
  • 678 Publications • 39,233 Citations
  • K. Davis
  • 641 Publications • 51,907 Citations
  • Publications
  • Influence
A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition
TLDR
The theoretical risk of cardiotoxicity associated with QTc prolongation should be balanced against the substantial clinical benefits associated with atypical antipsychotics and the likelihood of other toxicities.
Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease
TLDR
Compared to placebo, new AChEIs in development provide modest improvements in cognition for patients with mild to moderate AD, with improved tolerability profiles and more convenient dosing relative to tacrine.
Review of the acetylcholinesterase inhibitor galanthamine
TLDR
Evidence to date suggests galanthamine to be similar to other AChEIs in improving cognitive function in AD patients, which is well demonstrated by large-scale clinical trials.
Gender Differences in Depression and Antidepressant Pharmacokinetics and Adverse Events
TLDR
Clinicians should be aware that potential differences in antidepressant pharmacokinetics may exist, and a dosage adjustment may be necessary for women to ensure a favorable drug response, compliance, and decreased incidence of adverse events.
An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.
TLDR
Six male chronic schizophrenic patients concurrently treated with thiothixene or fluphenazine met DSM-III-R criteria for schizophrenia and historically demonstrated a lack of response to neuroleptics were administered glycine in fixed dosages.
An update on tardive dyskinesia.
The authors review recent research on definition, diagnosis, neuropathophysiology, treatment, management, and factors that increase risk of tardive dyskinesia, a severe and often unremitting movement…
Pramipexole in patients with early Parkinson's disease.
TLDR
Pramipexole appears to be promising agent in the treatment of early Parkinson's disease, as changes in scores from baseline to final measurement on the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III were significant.
Galantamine hydrobromide: an agent for Alzheimer's disease.
TLDR
Galantamine provides the clinician with another choice of an AChE inhibitor for use in treating AD and should be the principal factor weighed during formulary evaluations.
Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia.
RBC Cholinesterase Inhibition: A Useful Surrogate Marker for Cholinesterase Inhibitor Activity in Alzheimer Disease Therapy?
  • J. Sramek, N. Cutler
  • Biology, Medicine
    Alzheimer disease and associated disorders
  • 1 October 2000
TLDR
RBC cholinesterase inhibition is not a reliable surrogate marker for the activity of AChEIs as a class of drugs, and its usefulness as a dose optimization tool for individual agents has yet to be demonstrated clearly.
...
1
2
3
4
5
...